SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

Over the past two decades, management of pain in patients with systemic lupus erythematosus (SLE) has come to rely less on higher-risk therapies like opioids, although prescribing intensity remains ...

When people with systemic lupus erythematosus (SLE) actively participate in shared decision-making (SDM) about their disease with their doctors’, trust is likely to increase. A new study found that ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...

Please provide your email address to receive an email when new articles are posted on . The acceptable threshold for glucocorticoid use for lupus maintenance therapy should be 5 mg per day prednisone ...

The SLECRISK tool for predicting cardiovascular disease among patients with systemic lupus erythematosus produces more accurate predictions compared with the American College of Cardiology/American ...

Women with lupus face unique challenges regarding family planning and pregnancy. In a recent study, researchers looked at the impact of pregnancy planning and medical readiness on reproductive ...

Like in other chronic inflammatory disorders, achieving disease activity control in SLE requires the application of the treat-to-target strategy. This approach requires setting clear treatment targets ...

AJMC ®: What strategies have you found effective for increasing the screening and early diagnosis of lupus nephritis in patients with either diagnosed or suspected systemic lupus erythematosus (SLE)?